Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Estrogen Receptor Negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01791985
What this trial is testing

AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL)

Who this might be right for
Breast Cancer
Imperial College London 52
Post-approval studies (Phase 4)UnknownNCT00413491
What this trial is testing

National Screening in Denmark With MR Versus Mammography and Ultrasound of Women With BRCA1 or BRCA2 Mutations

Who this might be right for
Breast Cancer
Danish Breast Cancer Cooperative Group 300
Testing effectiveness (Phase 2)WithdrawnNCT01100489
What this trial is testing

Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer

Who this might be right for
Ductal Breast Carcinoma in SituEstrogen Receptor-negative Breast CancerEstrogen Receptor-positive Breast Cancer+13 more
Case Comprehensive Cancer Center
Large-scale testing (Phase 3)UnknownNCT03926091
What this trial is testing

Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer

Who this might be right for
Breast Cancer
Fudan University 2,172
Testing effectiveness (Phase 2)WithdrawnNCT06938711
What this trial is testing

A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Context Therapeutics Inc.
Early research (Phase 1)Study completedNCT03725436
What this trial is testing

ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

Who this might be right for
Advanced Malignant Solid NeoplasmAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8+12 more
M.D. Anderson Cancer Center 28
Not applicableStudy completedNCT02158507
What this trial is testing

Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer

Who this might be right for
Metastatic Triple Negative Breast Cancer
University of Alabama at Birmingham 20
Testing effectiveness (Phase 2)UnknownNCT02917005
What this trial is testing

PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Hamdy A. Azim 160
Testing effectiveness (Phase 2)UnknownNCT05880394
What this trial is testing

Study of Dotatate Imaging in Breast Cancer

Who this might be right for
Breast Cancer Stage IV
Hoag Memorial Hospital Presbyterian 30
Early research (Phase 1)Ended earlyNCT04504331
What this trial is testing

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

Who this might be right for
Breast CancerHER2-negative Breast CancerER Positive Breast Cancer+1 more
Jennifer Lee Caswell-Jin 4
Not applicableUnknownNCT05814224
What this trial is testing

Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA

Who this might be right for
Hormone Receptor Positive Breast CarcinomaBreast NeoplasmsNeoplasms, Breast+4 more
Centro di Riferimento Oncologico - Aviano 164
Testing effectiveness (Phase 2)Active Not RecruitingNCT01723774
What this trial is testing

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Who this might be right for
Breast Neoplasms
Washington University School of Medicine 84
Testing effectiveness (Phase 2)Study completedNCT01377324
What this trial is testing

Molecular Imaging of Fulvestrant Effects on Availability of ER Binding Sites

Who this might be right for
Metastatic Breast Cancer
University Medical Center Groningen 16
Testing effectiveness (Phase 2)Ended earlyNCT02774681
What this trial is testing

Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis

Who this might be right for
Breast Carcinoma Metastatic in the BrainEstrogen Receptor NegativeHER2/Neu Negative+4 more
Northwestern University 12
Testing effectiveness (Phase 2)UnknownNCT05577923
What this trial is testing

Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)

Who this might be right for
Metastatic Breast Cancer
Fudan University 126
Large-scale testing (Phase 3)Study completedNCT02437318
What this trial is testing

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 572
Early research (Phase 1)WithdrawnNCT01333423
What this trial is testing

Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)

Who this might be right for
Breast Cancer
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Ended earlyNCT00542191
What this trial is testing

Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer

Who this might be right for
Breast Cancer
Leo W. Jenkins Cancer Center 30
Testing effectiveness (Phase 2)Ended earlyNCT04191382
What this trial is testing

Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer

Who this might be right for
Breast Cancer
Sanofi 105
Large-scale testing (Phase 3)Study completedNCT00553358
What this trial is testing

Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 455
Next Page